Business Wire

European Commission Approves Symtuza® for the Treatment of HIV-1 In Adults and Adolescents in Europe

Del

Janssen-Cilag International NV (Janssen) today announced that the European Commission has approved the use of Symtuza® (darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF])1, a once-daily darunavir-based single-tablet regimen (STR), for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents aged 12 years and older with body weight of at least 40 kg. Cobicistat, emtricitabine and tenofovir alafenamide are from Gilead Sciences, Inc.

The only darunavir-based STR indicated for the treatment of this patient group, Symtuza® combines the proven efficacy and durability of darunavir with the improved renal laboratory and bone mineral density profile of F/TAF as compared to F/TDF (emtricitabine/tenofovir disoproxil fumarate). It is the only approved treatment to offer the convenience of a STR alongside the high genetic barrier to resistance provided by darunavir.

“There are almost one million people in the European Union currently living with HIV. The availability of a single-treatment regimen with a high barrier to resistance mutations eliminates the need for separate tablets, reducing the burden of pills on daily life for patients, and helping them to achieve improved treatment adherence and viral suppression,” said Jean-Michel Molina, Professor of Infectious Diseases at the University of Paris Diderot.

“At Janssen, we are committed to developing effective and innovative treatments which address the issues of adherence and resistance. Today’s approval by the European Commission demonstrates our efforts to treat HIV more simply, helping all those living with HIV to achieve an undetectable viral load while enjoying an improved quality of life,” said Lawrence M. Blatt, Ph.D., Global Therapeutic Area Head, Janssen Infectious Diseases Therapeutics.

Results from a bioequivalence study that compared Symtuza® with the combined administration of the separate agents darunavir [D] 800 mg, cobicistat [C] 150 mg, and emtricitabine/tenofovir alafenamide [FTC/TAF] 200 mg/10 mg fixed-dose combination were presented at the International AIDS Society (IAS) conference in Paris, France in July.2 These results confirmed that the once-daily STR is bioequivalent to the combined administration of the separate agents, as well as demonstrating that the STR is well tolerated.

In addition, results from the pivotal Phase 3 EMERALD study presented at IAS showed that the once-daily STR containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg [D/C/F/TAF] had a low cumulative virologic rebound rate and a high virologic suppression rate at 24 weeks in HIV-1 positive, virologically suppressed adults who switched from a standard boosted protease inhibitor (PI) plus tenofovir/emtricitabine regimen. A Phase 3 clinical trial programme investigating the efficacy and safety of the darunavir-based combination is ongoing. In October, EMERALD 48-week data will be presented at ID Week 2017 in San Diego, California, USA, and 48-week data from the Phase 3 AMBER trial in antiretroviral therapy (ART) naïve patients will be presented at the European AIDS Clinical Society (EACS) Conference in Milan, Italy.3,4

On 20 July, the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for Symtuza®.5 This subsequent European Commission approval allows Janssen to market Symtuza® in all countries in the European Union and European Economic Area.1

###

Notes to editors

On 23 December 2014, Janssen and Gilead Sciences International Ltd amended a licensing agreement for the development and commercialisation of a once-daily STR combination of darunavir and Gilead's TAF, emtricitabine and cobicistat. Under the terms of the agreement, Janssen and its affiliates are responsible for the manufacturing, registration, distribution and commercialisation of this STR worldwide.

About Symtuza ®

In the European Union, Symtuza® is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg). Genotypic testing should guide the use of Symtuza®.

Symtuza® is a fixed-dose combination of four active substances (darunavir, cobicistat, emtricitabine and tenofovir alafenamide), available as 800 mg/150 mg/200 mg/10 mg film-coated tablets. Darunavir inhibits the HIV protease and prevents the formation of mature infectious virus particles. Emtricitabine and tenofovir alafenamide are substrates and competitive inhibitors of HIV reverse transcriptase. After phosphorylation, they are incorporated into the viral DNA chain, resulting in chain termination. Cobicistat enhances the systemic exposure of darunavir and has no direct antiviral effect.

About the Janssen Pharmaceutical Companies of Johnson & Johnson

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com/emea and follow us at @JanssenEMEA.

Cautions Concerning Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding development of potential preventive and treatment regimens for HIV. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Janssen Pharmaceutical Companies and Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new indications and therapeutic combinations; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behaviour and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the year ended January 1, 2017, including under “Item 1A Risk Factors,” its most recently filed Quarterly Report on Form 10-Q, including in the section captioned “Cautionary Note Regarding Forward-Looking Statements,” and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies or Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

1 European Medicines Agency http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004391/smops/Positive/human_smop_001176.jsp&mid=WC0b01ac058001d127

2 9th IAS Conference on HIV Science 2017 http://www.ias2017.org/Portals/1/Files/IAS2017_LO.compressed.pdf?ver=2017-07-27-211231-197

3 ID Week 2017 https://idsa.confex.com/idsa/2017/webprogram/start.html

4 16th European AIDS Conference http://www.eacs-conference2017.com/index.php?article_id=147

5 European Medicines Agency, Symtuza Summary of opinion http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/004391/WC500231710.pdf

Contact information

Janssen
MEDIA CONTACT:
Inès Hammer
+ 33 6 88 09 33 35
IHAMMER@its.jnj.com
or
INVESTOR RELATIONS:
Lesley Fishman
Phone: +1 732-524-3922
or
Joseph J. Wolk
Phone: +1 732-524-1142

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Keio Plaza Hotel Tokyo Hosts "Princess Mermaid Sweets Buffet"21.6.2018 14:05Pressemelding

Keio Plaza Hotel Tokyo (KPH), one of Japan’s most prestigious international hotels located in Shinjuku, Tokyo, will host the “Princess Mermaid Sweets Buffet” in commemoration of the fairy tale written by the Danish author Hans Christian Andersen at our All Day Dining Restaurant “Jurin” from July 1 (Sunday) to September 30 (Sunday), 2018. This year’s buffet will offer a wide range of colorful desserts based on the “deep blue color of the cornflower” and other various flowers specially prepared by our patissiers and patterned after various sea creatures reminiscent of characters portrayed in the Little Mermaid fairy tale. Some of delectable desserts include clams made of chocolate and “deep sea mousse” made in a colorful blue using passion fruit and pineapple flavorings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180621005383/en/ A wide range of colorful desserts based on the deep blue color and patterned after various sea

Clearhaus gir norske nettbutikker Apple Pay 21.6.2018 13:35Pressemelding

Apples mobilbetalingstjeneste, Apple Pay, har nettopp blitt lansert i Norge. Banker som Santander og Nordea er de første som introduserer tjenesten til norske forbrukere. Samtidig sørger den danske innløsningsvirksomheten Clearhaus for å gjøre den innovative, nye betalingsmetoden tilgjengelig i norske nettbutikker. Mobillommebok-teknologi som Apple Pay endrer hvordan folk kjøper og selger varer i butikker, i apper og på nettet. Apple Pay drives av Visa- og Mastercards tokeniseringsteknologi. Tjenesten gjør det mulig for iPhone-, Apple Watch-, iPad- og Mac-brukere å betale for varer på en enkel og sikker måte. Ved bruk av Apple Pay på nettet, trenger ikke forbrukere lenger å taste inn 16 kreditt- eller debetkortsiffer, utløpsdatoer og sikkerhetskoder. Etter å ha gjennomført et enkelt engangsoppsett med et kreditt- eller debetkort, kan brukere enkelt foreta kjøp i fysiske butikker eller i nettbutikker. Dette gjøres ved å plassere fingeren på touch id-platen eller ved å bruke ansiktsgjenk

Wipro Positioned as a Leader in Gartner’s Magic Quadrant 2018 for Oracle Application Services, Worldwide21.6.2018 13:22Pressemelding

Wipro Limited (NYSE: WIT) (BSE: 507685) (NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that it has been positioned as a Leader in Gartner’s Magic Quadrant 2018 for Oracle Application Services, Worldwide. The report authored by Alan H Stanley, Susanne Matson, Jim Longwood and Allan Wilkins was published on February 28, 2018. This Magic Quadrant is focused on the full life-cycle of Oracle application services, spanning across project-based implementation and multi-year application management services (AMS). The report evaluated 19 service providers from across the globe and placed Wipro in the Leaders quadrant. Wipro is positioned the highest for its ‘ability to execute’ among all service providers. Please click here to view the complete Magic Quadrant report for Oracle Application Services 2018, Worldwide. Additionally, Wipro has been positioned in the Top 3 for three use cases namely, Implementation services, Man

Seoul Semiconductor Captures the Home Lighting Market with Its Innovative LED SunLike Technology21.6.2018 13:00Pressemelding

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a market leader in LED (light emitting diode) design and manufacturing, has launched into the global home lighting market with its innovative LED technology “SunLike.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180621005553/en/ Seoul Semiconductor, a market leader in LED design and manufacturing, launched into the global home lighting market with its innovative LED technology SunLike. SunLike implementing a spectrum similar to sunlight by lowering the blue light wavelength compared to an ordinary LED. (Graphic: Business Wire) Seoul Semiconductor announced that Mimi Lighting, a Korean LED lighting company, applied an innovative technology SunLike to the company’s home lighting products, which to be launched in the 3Q. SunLike applied to this home lighting is a natural light LED, which minimizes the disadvantages of artificial lighting and maximizes the advantages of natural l

MYbank Launches Star Plan to Support 1,000 Financial Institutions to Serve 30 Million SMEs in the Next Three Years21.6.2018 12:56Pressemelding

MYbank, a leading online private commercial bank in China with a focus on SME financing, today announced the launch of the Star Plan to open up its proven AI, computing and risk management capabilities to financial institutions in China. Through sharing these technological capabilities, MYbank aims to enable 1,000 financial institutions to provide more cost-effective financing services to 30 million SMEs and farmers in China in the next three years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180621005666/en/ Announcing the launch of the Star Plan at the 2018 SME Financing Summit in Hangzhou, Eric Jing, Chairman of MYbank, Executive Chairman and CEO of Ant Financial, said, “The widespread application of advanced technologies in the SME financing space has dramatically improved risk management and lowered costs. With these innovations, we can unlock new opportunities for financial institutions and enable them to sustainabl

IFA 2018 : LG CEO and CTO to Outline Ambitious Strategy for ThinQ AI at IFA Opening Keynote21.6.2018 12:28Pressemelding

LG Electronics (LG) Chief Executive Officer Jo Seong-Jin and Chief Technology Officer Dr. I.P. Park will deliver a joint opening keynote at IFA 2018 to outline their vision for LG’s ThinQ strategy for Artificial Intelligence. The first IFA keynote for both executives, titled Think Wise, Be Free: Living Freer with AI will be delivered on Friday, August 31, in Hall 26b at Messe Berlin. With interest in all things AI at a peak, CEO Jo will provide his insight into how LG’s AI strategy will change customers’ lives based on its unique philosophy of an “open platform, open partnership and open connectivity”. Dr. Park will show how this technology comes to life in everyday products like refrigerators, TVs and washing machines, and how LG’s open AI strategy benefits consumers thanks to its focus of giving them both control and convenience. “The IFA Keynotes provide CEOs and top executives with a global media platform for forward thinking ideas and strategies,” said Jens Heithecker, Messe Berli